dalteparin has been researched along with Disease Exacerbation in 33 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although congenital afibrinogenemia is a rare autosomal recessive bleeding disorder, it can be more frequently encountered in countries where consanguineous marriages are common." | 7.81 | A case of congenital afibrinogenemia complicated with thromboembolic events that required repeated amputations. ( Işik, B; Karakukcu, M; Mutlu, FT; Ozdemir, MA; Patiroglu, T; Unal, E; Yilmaz, E, 2015) |
| "The aim of this study was to examine the effect of the antithrombotic drugs aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of liver cirrhosis and to determine if these two drugs are beneficial in animals with advanced fibrosis or with established cirrhosis undergoing partial hepatectomy." | 7.74 | The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis. ( Assy, N; Hussein, O; Khalil, A; Luder, A; Paizi, M; Spira, G; Szvalb, S, 2007) |
| "ESSENTIALS: Does thrombus stability alter the presentation of venous thromboembolism and do anticoagulants alter this? In a murine model, we imaged a femoral vein thrombus and quantified emboli in the pulmonary arteries." | 5.43 | Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism. ( Gross, PL; Ni, R; Saldanha, LJ; Shaya, SA; Vaezzadeh, N; Zhou, J, 2016) |
| "Although congenital afibrinogenemia is a rare autosomal recessive bleeding disorder, it can be more frequently encountered in countries where consanguineous marriages are common." | 3.81 | A case of congenital afibrinogenemia complicated with thromboembolic events that required repeated amputations. ( Işik, B; Karakukcu, M; Mutlu, FT; Ozdemir, MA; Patiroglu, T; Unal, E; Yilmaz, E, 2015) |
| "The aim of this study was to examine the effect of the antithrombotic drugs aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of liver cirrhosis and to determine if these two drugs are beneficial in animals with advanced fibrosis or with established cirrhosis undergoing partial hepatectomy." | 3.74 | The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis. ( Assy, N; Hussein, O; Khalil, A; Luder, A; Paizi, M; Spira, G; Szvalb, S, 2007) |
| " The first received low-molecular-weight heparin for 10 days at therapeutic dosage (nadroparin 180 anti-activated factor X units once daily) and compression therapy for three months, and the second received compression therapy alone." | 2.75 | Therapy of isolated calf muscle vein thrombosis: a randomized, controlled study. ( Beyer, J; Buschmann, L; Halbritter, K; Rastan, A; Schellong, S; Schwarz, T, 2010) |
| " These assays may provide useful markers to guide appropriate dalteparin (and other low-molecular weight heparin) dosing schedules to optimize anticancer effects of dalteparin in APC." | 2.75 | Weight-adjusted dalteparin for prevention of vascular thromboembolism in advanced pancreatic cancer patients decreases serum tissue factor and serum-mediated induction of cancer cell invasion. ( Echrish, H; Ettelaie, C; Gardiner, E; Greenman, J; Li, C; Madden, LA; Maraveyas, A, 2010) |
| "ESSENTIALS: Does thrombus stability alter the presentation of venous thromboembolism and do anticoagulants alter this? In a murine model, we imaged a femoral vein thrombus and quantified emboli in the pulmonary arteries." | 1.43 | Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism. ( Gross, PL; Ni, R; Saldanha, LJ; Shaya, SA; Vaezzadeh, N; Zhou, J, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (30.30) | 29.6817 |
| 2010's | 16 (48.48) | 24.3611 |
| 2020's | 7 (21.21) | 2.80 |
| Authors | Studies |
|---|---|
| Wilts, IT | 1 |
| Hutten, BA | 1 |
| Meijers, JCM | 1 |
| Spek, CA | 1 |
| Büller, HR | 1 |
| Kamphuisen, PW | 1 |
| Nagy, Z | 1 |
| Turcsik, V | 1 |
| Blaskó, G | 1 |
| Asero, R | 1 |
| Tedeschi, A | 1 |
| Cugno, M | 1 |
| Schwarz, T | 1 |
| Buschmann, L | 1 |
| Beyer, J | 1 |
| Halbritter, K | 1 |
| Rastan, A | 1 |
| Schellong, S | 1 |
| Chen, S | 1 |
| Schmidt, B | 1 |
| Tohoku, S | 1 |
| Trolese, L | 1 |
| Bordignon, S | 1 |
| Chun, KRJ | 1 |
| Glueck, CJ | 3 |
| Freiberg, RA | 3 |
| Wang, P | 3 |
| Massabeti, R | 1 |
| Cipriani, MS | 1 |
| Valenti, I | 1 |
| Abrams, RMC | 1 |
| Kim, BD | 1 |
| Markantone, DM | 1 |
| Reilly, K | 1 |
| Paniz-Mondolfi, AE | 1 |
| Gitman, MR | 1 |
| Choo, SY | 1 |
| Tse, W | 1 |
| Robinson-Papp, J | 1 |
| Audley, GG | 1 |
| Frankenfeld, P | 1 |
| Dlamini, S | 1 |
| Raubenheimer, P | 1 |
| Hoare, J | 1 |
| Cairncross, L | 1 |
| Van den Berg, R | 1 |
| Gule, MV | 1 |
| Calligaro, G | 1 |
| Sukhdeo, S | 1 |
| Negroponte, E | 1 |
| Rajasekhar, H | 1 |
| Gaur, S | 1 |
| Horton, DB | 1 |
| Malhotra, A | 1 |
| Moorthy, LN | 1 |
| Qian, C | 1 |
| Huhtakangas, J | 1 |
| Juvela, S | 1 |
| Bode, MK | 1 |
| Tatlisumak, T | 1 |
| Savolainen, M | 1 |
| Numminen, H | 1 |
| Ollikainen, J | 1 |
| Luostarinen, L | 1 |
| Kupila, L | 1 |
| Tetri, S | 1 |
| Ohta, H | 1 |
| Miyake, T | 1 |
| Shimizu, T | 1 |
| Sonoda, H | 1 |
| Ueki, T | 1 |
| Kaida, S | 1 |
| Yamaguchi, T | 1 |
| Iida, H | 1 |
| Tani, M | 1 |
| Pastorek, RA | 1 |
| Cripps, MW | 1 |
| Bernstein, IH | 1 |
| Scott, WW | 1 |
| Madden, CJ | 1 |
| Rickert, KL | 1 |
| Wolf, SE | 1 |
| Phelan, HA | 1 |
| Ozdemir, MA | 1 |
| Işik, B | 1 |
| Patiroglu, T | 1 |
| Karakukcu, M | 1 |
| Mutlu, FT | 1 |
| Yilmaz, E | 1 |
| Unal, E | 1 |
| Giuliani, J | 1 |
| Martelli, S | 1 |
| Piacentini, P | 1 |
| Bonetti, A | 1 |
| Assad, M | 1 |
| Coffin-Pichonnet, S | 1 |
| Billotte, C | 1 |
| Denion, É | 1 |
| Mir, T | 1 |
| Layliev, J | 1 |
| Glickman, LT | 1 |
| Karow, A | 1 |
| Hainmann, I | 1 |
| Nakamura, L | 1 |
| Budde, U | 1 |
| Mueller, C | 1 |
| Zieger, B | 1 |
| Minshall, CT | 1 |
| Eriksson, EA | 1 |
| Leon, SM | 1 |
| Doben, AR | 1 |
| McKinzie, BP | 1 |
| Fakhry, SM | 1 |
| Gris, JC | 1 |
| Chauleur, C | 1 |
| Molinari, N | 1 |
| Marès, P | 1 |
| Fabbro-Peray, P | 1 |
| Quéré, I | 1 |
| Lefrant, JY | 1 |
| Haddad, B | 1 |
| Dauzat, M | 1 |
| Monroe, VS | 1 |
| Kerensky, RA | 1 |
| Rivera, E | 1 |
| Smith, KM | 1 |
| Pepine, CJ | 1 |
| Robert, F | 1 |
| Busby, E | 1 |
| Marques, MB | 1 |
| Reynolds, RE | 1 |
| Carey, DE | 1 |
| Sieve, L | 1 |
| Assy, N | 1 |
| Hussein, O | 1 |
| Khalil, A | 1 |
| Luder, A | 1 |
| Szvalb, S | 1 |
| Paizi, M | 1 |
| Spira, G | 1 |
| Kinori, M | 1 |
| Saar, N | 1 |
| Justo, D | 1 |
| Almog, R | 1 |
| de Bièvre, MA | 1 |
| Vrij, AA | 1 |
| Schoon, EJ | 1 |
| Dijkstra, G | 1 |
| de Jong, AE | 1 |
| Oberndorff-Klein Woolthuis, AH | 1 |
| Hemker, HC | 1 |
| Stockbrügger, RW | 1 |
| Shaya, SA | 1 |
| Saldanha, LJ | 1 |
| Vaezzadeh, N | 1 |
| Zhou, J | 1 |
| Ni, R | 1 |
| Gross, PL | 1 |
| Maraveyas, A | 1 |
| Ettelaie, C | 1 |
| Echrish, H | 1 |
| Li, C | 1 |
| Gardiner, E | 1 |
| Greenman, J | 1 |
| Madden, LA | 1 |
| Altinbas, M | 1 |
| Coskun, HS | 1 |
| Er, O | 1 |
| Ozkan, M | 1 |
| Eser, B | 1 |
| Unal, A | 1 |
| Cetin, M | 1 |
| Soyuer, S | 1 |
| Wallentin, L | 1 |
| Lagerqvist, B | 1 |
| Husted, S | 1 |
| Kontny, F | 1 |
| Ståhle, E | 1 |
| Swahn, E | 1 |
| Bauer, AT | 1 |
| Suckau, J | 1 |
| Frank, K | 1 |
| Desch, A | 1 |
| Goertz, L | 1 |
| Wagner, AH | 1 |
| Hecker, M | 1 |
| Goerge, T | 1 |
| Umansky, L | 1 |
| Beckhove, P | 1 |
| Utikal, J | 1 |
| Gorzelanny, C | 1 |
| Diaz-Valdes, N | 1 |
| Umansky, V | 1 |
| Schneider, SW | 1 |
| Sprigg, N | 1 |
| Gray, LJ | 1 |
| Bath, PM | 1 |
| Lindenstrøm, E | 1 |
| Boysen, G | 1 |
| De Deyn, PP | 1 |
| Friis, P | 1 |
| Leys, D | 1 |
| Marttila, R | 1 |
| Olsson, JE | 1 |
| O'Neill, D | 1 |
| Ringelstein, EB | 1 |
| van der Sande, JJ | 1 |
| Turpie, AG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Phase III-b, Multi-centre, Open-label, Parallel Study of Enoxaparin (Low Molecular Weight Heparin) Given Concomitantly With Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Gastric and Gastro-oesophageal Cancer[NCT00718354] | Phase 3 | 740 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| A Clinical Trial of Conservative Versus Routine Invasive Management in Patients With Prior Coronary Artery Bypass Surgery in Patients With a Non-ST Elevation Acute Coronary Syndrome: a Pilot Trial and Registry.[NCT01895751] | Phase 4 | 60 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| Evaluation of a Strategy Guided by Imaging Versus Systematic Coronary Angiography in Elderly Patients With Ischemia: a Multicentric Randomized Non Inferiority Trial.[NCT03289728] | 1,756 participants (Anticipated) | Interventional | 2018-04-04 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for dalteparin and Disease Exacerbation
| Article | Year |
|---|---|
Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes.
Topics: Abciximab; Acute Disease; Angina, Unstable; Antibodies, Monoclonal; C-Reactive Protein; Coronary Art | 2003 |
11 trials available for dalteparin and Disease Exacerbation
| Article | Year |
|---|---|
Association between protein C levels and mortality in patients with advanced prostate, lung and pancreatic cancer.
Topics: Aged; Anticoagulants; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female | 2017 |
The effect of LMWH (Nadroparin) on tumor progression.
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; | 2009 |
Therapy of isolated calf muscle vein thrombosis: a randomized, controlled study.
Topics: Adult; Aged; Anticoagulants; Combined Modality Therapy; Compression Bandages; Disease Progression; D | 2010 |
Early vs. late enoxaparin for the prevention of venous thromboembolism in patients with ICH: A double blind placebo controlled multicenter study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Cerebral Hemorrhage; Disease Progression; Double-Blind Meth | 2021 |
Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial.
Topics: Anticoagulants; Aspirin; Cohort Studies; Disease Progression; Enoxaparin; Female; Follow-Up Studies; | 2011 |
Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung | 2003 |
Randomized, placebo-controlled trial of low molecular weight heparin in active ulcerative colitis.
Topics: Adult; Colitis, Ulcerative; Colonoscopy; Disease Progression; Dose-Response Relationship, Drug; Doub | 2007 |
Weight-adjusted dalteparin for prevention of vascular thromboembolism in advanced pancreatic cancer patients decreases serum tissue factor and serum-mediated induction of cancer cell invasion.
Topics: Aged; Dalteparin; Disease Progression; Female; Humans; Male; Middle Aged; Molecular Weight; Neoplasm | 2010 |
A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer.
Topics: Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; | 2004 |
Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography | 2000 |
Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography | 2000 |
Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography | 2000 |
Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography | 2000 |
Stroke severity, early recovery and outcome are each related with clinical classification of stroke: data from the 'Tinzaparin in Acute Ischaemic Stroke Trial' (TAIST).
Topics: Aged; Aged, 80 and over; Brain Infarction; Brain Ischemia; Cerebral Hemorrhage; Disease Progression; | 2007 |
21 other studies available for dalteparin and Disease Exacerbation
| Article | Year |
|---|---|
Heparin and tranexamic Acid therapy may be effective in treatment-resistant chronic urticaria with elevated d-dimer: a pilot study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Cetirizine; Chr | 2010 |
Transesophageal echocardiography-guided closure of electrically isolated left atrial appendage to constrain a rapidly growing thrombus despite anticoagulation and sinus rhythm.
Topics: Action Potentials; Aged, 80 and over; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Atrial | 2020 |
Long-term Anticoagulation Prevents Progression of Stages I and II Primary Osteonecrosis of the Hip in Patients With Familial Thrombophilia.
Topics: Adult; Anticoagulants; Disease Progression; Enoxaparin; Female; Femur Head Necrosis; Fibrinolysis; F | 2020 |
Covid-19: A systemic disease treated with a wide-ranging approach: A case report.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Azithromycin; China; Coronavirus Infecti | 2020 |
Severe rapidly progressive Guillain-Barré syndrome in the setting of acute COVID-19 disease.
Topics: Acute Disease; Aged; Anticoagulants; Betacoronavirus; Coronavirus Infections; COVID-19; Disease Prog | 2020 |
Prolonged treatment of COVID-19 pneumonia with high-flow nasal oxygen: A story of oxygen and resilience.
Topics: Anti-Bacterial Agents; Anticoagulants; Anxiety; Blood Gas Analysis; Cannula; Citalopram; Counseling; | 2020 |
Acute respiratory distress syndrome and COVID-19 in a child with systemic lupus erythematosus.
Topics: Antiviral Agents; Child, Preschool; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Cy | 2021 |
The impact of pharmacological thromboprophylaxis and disease-stage on postoperative bleeding following colorectal cancer surgery.
Topics: Aged; Anticoagulants; Colorectal Neoplasms; Disease Progression; Elective Surgical Procedures; Enoxa | 2019 |
The Parkland Protocol's modified Berne-Norwood criteria predict two tiers of risk for traumatic brain injury progression.
Topics: Adult; Aged; Brain Injuries; Clinical Protocols; Disease Progression; Enoxaparin; Female; Fibrinolyt | 2014 |
A case of congenital afibrinogenemia complicated with thromboembolic events that required repeated amputations.
Topics: Afibrinogenemia; Amputation, Surgical; Anemia; Anticoagulants; Blood Coagulation Tests; Disease Prog | 2015 |
Medical treatment of osteonecrosis of the knee associated with thrombophilia-hypofibrinolysis.
Topics: Adult; Aged; Blood Coagulation Disorders; Disease Progression; Enoxaparin; Female; Fibrinolysis; Fib | 2014 |
Thromboembolic disease in advanced colorectal cancer treated with chemotherapy and bevacizumab: a case of real "pan-thrombosis".
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2015 |
[Acute unilateral arteritic anterior ischemic optic neuropathy becoming bilateral despite corticosteroid therapy].
Topics: Acute Disease; Aged; Alzheimer Disease; Anti-Inflammatory Agents; Anticoagulants; Aspirin; Disease P | 2016 |
Massive spontaneous hematoma from chronic enoxaparin (Lovenox) use.
Topics: Abdominal Wall; Acute Kidney Injury; Anticoagulants; Combined Modality Therapy; Disease Progression; | 2010 |
Progressive thrombosis in a 13-year-old girl with trisomy 21 under therapy with low molecular weight heparin.
Topics: Adolescent; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Antithrombins; | 2011 |
Safety and efficacy of heparin or enoxaparin prophylaxis in blunt trauma patients with a head abbreviated injury severity score >2.
Topics: Abbreviated Injury Scale; Anticoagulants; Brain Injuries; Disease Progression; Enoxaparin; Heparin; | 2011 |
Enoxaparin prevents progression of stages I and II osteonecrosis of the hip.
Topics: Arthroplasty, Replacement, Hip; Blood Coagulation Disorders; Disease Progression; Enoxaparin; Female | 2005 |
The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis.
Topics: Animals; Aspartate Aminotransferases; Aspirin; Bilirubin; Disease Progression; Enoxaparin; Fibrinoly | 2007 |
Determination of anti-Xa levels in pregnant women treated with low molecular weight heparins for prevention of recurrent venous thromboembolism: a case report and review of the literature.
Topics: Adult; Disease Progression; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Female; Heparin, Low-Molecu | 2008 |
Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism.
Topics: Animals; Anticoagulants; Antithrombins; Dabigatran; Dalteparin; Disease Models, Animal; Disease Prog | 2016 |
von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans.
Topics: ADAM Proteins; ADAMTS13 Protein; Animals; Blood Coagulation; Blood Platelets; Disease Models, Animal | 2015 |